PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
1380591-0	1992	Effects of isradipine on plasma renin activity in sodium-loaded and -depleted conscious rabbits.	Isradipine	11-21	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	32-37
1380591-2	1992	We therefore investigated whether modest changes in the salt balance might alter the acute response of the renin-angiotensin system to the calcium antagonist isradipine in conscious rabbits.	Isradipine	158-168	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	107-112
1533606-1	1992	Effects of exercise and of the calcium antagonist, isradipine, on plasma ANP.	Isradipine	51-61	natriuretic peptide A	Homo sapiens	73-76
1533606-9	1992	During the first exercise period, before ingestion of isradipine or placebo, the median level of ANP increased from 74 pg/ml at rest to 97 pg/ml at exhaustion (P less than 0.0002) (all patients).	Isradipine	54-64	natriuretic peptide A	Homo sapiens	97-100
1376829-5	1992	The new dihydropyridine calcium antagonist isradipine, when tested in a group of patients with mild hypertension, resulted in a decrease in platelet aggregation, a shortened euglobulin clot-lysis time, and a dramatic increase in t-PA (tissue-plasminogen activator) activity after 14 days of treatment.	Isradipine	43-53	chromosome 20 open reading frame 181	Homo sapiens	229-233
1483483-2	1992	Isradipine reduced intraarterial blood pressure by decreasing the total (placebo 5.1 U.mPa-1.s-1; isradipine 3.9 U.mPa-1.s-1), and renal (placebo 48.9 U.mPa-1.s-1, isradipine 35.4 U.mPa-1.s-1) vascular hindrance, the blood viscosity being unchanged.	Isradipine	0-10	PAXIP1 associated glutamate rich protein 1A	Mus musculus	87-92
1483483-2	1992	Isradipine reduced intraarterial blood pressure by decreasing the total (placebo 5.1 U.mPa-1.s-1; isradipine 3.9 U.mPa-1.s-1), and renal (placebo 48.9 U.mPa-1.s-1, isradipine 35.4 U.mPa-1.s-1) vascular hindrance, the blood viscosity being unchanged.	Isradipine	0-10	PAXIP1 associated glutamate rich protein 1A	Mus musculus	115-120
1483483-2	1992	Isradipine reduced intraarterial blood pressure by decreasing the total (placebo 5.1 U.mPa-1.s-1; isradipine 3.9 U.mPa-1.s-1), and renal (placebo 48.9 U.mPa-1.s-1, isradipine 35.4 U.mPa-1.s-1) vascular hindrance, the blood viscosity being unchanged.	Isradipine	0-10	PAXIP1 associated glutamate rich protein 1A	Mus musculus	115-120
1483483-2	1992	Isradipine reduced intraarterial blood pressure by decreasing the total (placebo 5.1 U.mPa-1.s-1; isradipine 3.9 U.mPa-1.s-1), and renal (placebo 48.9 U.mPa-1.s-1, isradipine 35.4 U.mPa-1.s-1) vascular hindrance, the blood viscosity being unchanged.	Isradipine	0-10	PAXIP1 associated glutamate rich protein 1A	Mus musculus	115-120
1376829-5	1992	The new dihydropyridine calcium antagonist isradipine, when tested in a group of patients with mild hypertension, resulted in a decrease in platelet aggregation, a shortened euglobulin clot-lysis time, and a dramatic increase in t-PA (tissue-plasminogen activator) activity after 14 days of treatment.	Isradipine	43-53	chromosome 20 open reading frame 181	Homo sapiens	235-263
1376842-6	1992	Comparison of systolic (SBP) and diastolic (DBP) blood pressures with isradipine indicated that there were significantly greater average decreases in SBP at 0600-0800 h than at 1800-2000 h (p = 0.038), and at 0800-1100 h than at 2000-2300 h (p = 0.045).	Isradipine	70-80	selenium binding protein 1	Homo sapiens	150-153
1839656-4	1991	After treatment with isradipine sBP fell from 168.0 to 148.1 and dBP from 102.7 to 86.7 mmHg.	Isradipine	21-31	selenium binding protein 1	Homo sapiens	32-35
1647962-5	1991	The activation by lower doses of ET-1, but not the inhibition by higher doses of ET-1, of the BK channel was blocked by 0.1 microM PN 200-110, a Ca2+ channel blocker.	Isradipine	131-141	endothelin 1	Homo sapiens	33-37
1827005-12	1991	The influence of isradipine on plasma renin activity (PRA) and aldosterone levels was followed by measuring values at rest and during exercise.	Isradipine	17-27	renin	Homo sapiens	38-43
1827016-7	1991	These data show that the levels of plasma apolipoprotein A-I, a strong predictor of coronary heart disease, are favorably affected by isradipine of either formulation.	Isradipine	134-144	apolipoprotein A1	Homo sapiens	42-60
1836066-1	1991	Relationship between serum erythropoietin, blood hemoglobin and lung function--effect of the calcium antagonist isradipine on serum erythropoietin.	Isradipine	112-122	erythropoietin	Homo sapiens	132-146
2143980-4	1990	Clinical trials indicate that isradipine is an effective antihypertensive agent, suitable as monotherapy or in combination with beta-blockers, diuretics or ACE inhibitors, for long term treatment of mild to moderate hypertension.	Isradipine	30-40	angiotensin I converting enzyme	Homo sapiens	156-159
2172518-16	1990	[3H](+)-isradipine binding capacity was increased 1.8-fold by NGF in depolarized PC12 cells while no change was observed in mutant cells after NGF or ouabain.	Isradipine	4-18	nerve growth factor	Rattus norvegicus	62-65
34766657-7	2022	Participants given 10 mg/day ER isradipine had significantly smaller total and part 3 UPDRS scores at the end of the trial than did the placebo cohort.	Isradipine	32-42	epiregulin	Homo sapiens	29-31
2172518-13	1990	By contrast, the dihydropyridine (DHP) isradipine reduced I-30 in NGF-treated cells by 30 +/- 8 pA and in native cells by 20 +/- 3 pA. 4.	Isradipine	39-49	nerve growth factor	Rattus norvegicus	66-69
2140943-0	1990	The calcium antagonist isradipine and its effect on blood pressure related to plasma renin activity.	Isradipine	23-33	renin	Homo sapiens	85-90
2140943-1	1990	This study was designed to test the hypothesis that peripheral vein plasma renin activity is a determinant of the magnitude of the hypotensive effect of the calcium antagonist Isradipine when given to mild to moderately severe essential hypertensives.	Isradipine	176-186	renin	Homo sapiens	75-80
2140943-2	1990	There was significant relationship between plasma renin activity and blood pressure reduction by Isradipine.	Isradipine	97-107	renin	Homo sapiens	50-55
2140943-5	1990	Thus, low peripheral vein plasma renin activity is a determinant (marker) of the hypotensive effect of Isradipine in mild to moderately severe uncomplicated essential hypertensives.	Isradipine	103-113	renin	Homo sapiens	33-38
35142739-13	2022	Finally, double heterozygosity rats with CACNA1D p.D307G/p.R1561Q or CACNA1D p.D307G/p.V936I further accelerated the rise of SBP compared with p.D307G mutation rats, and isradipine and BQ-123 reduced BP to the same extent in CACNA1D p.D307G/p.R1561Q rats.	Isradipine	170-180	calcium voltage-gated channel subunit alpha1 D	Rattus norvegicus	41-48
34411234-8	2022	The electrophysiological changes were sensitive to pharmacological blockade of CaV1.3 (isradipine, 100 nM).	Isradipine	87-97	calcium channel, voltage-dependent, L type, alpha 1D subunit	Mus musculus	79-85
34353274-14	2022	Furthermore, the interaction of isradipine with FAK-1 was compared with 7 native ligands and was found to show significant interaction with a binding energy of -8.62, -7.27, -7.69, -5.67, -5.41, -7.44, -8.21.	Isradipine	32-42	protein tyrosine kinase 2	Homo sapiens	48-53
34353274-17	2022	CONCLUSION: Isradipine could act as a potential inhibitor of different proteases and FAK-1 associated with tumor growth initiation, progression, and metastasis.	Isradipine	12-22	protein tyrosine kinase 2	Homo sapiens	85-90
35142739-13	2022	Finally, double heterozygosity rats with CACNA1D p.D307G/p.R1561Q or CACNA1D p.D307G/p.V936I further accelerated the rise of SBP compared with p.D307G mutation rats, and isradipine and BQ-123 reduced BP to the same extent in CACNA1D p.D307G/p.R1561Q rats.	Isradipine	170-180	calcium voltage-gated channel subunit alpha1 D	Rattus norvegicus	69-76
35142739-13	2022	Finally, double heterozygosity rats with CACNA1D p.D307G/p.R1561Q or CACNA1D p.D307G/p.V936I further accelerated the rise of SBP compared with p.D307G mutation rats, and isradipine and BQ-123 reduced BP to the same extent in CACNA1D p.D307G/p.R1561Q rats.	Isradipine	170-180	spermine binding protein	Rattus norvegicus	125-128
2523655-4	1989	In rats, the dose-response curves for pressor effects to angiotensin II were shifted in parallel to the right after treatment with isradipine, but not with prazosin and dihydralazine, suggesting that the antivasoconstrictor effect of isradipine was of a specific type.	Isradipine	131-141	angiotensinogen	Rattus norvegicus	57-71
2523655-4	1989	In rats, the dose-response curves for pressor effects to angiotensin II were shifted in parallel to the right after treatment with isradipine, but not with prazosin and dihydralazine, suggesting that the antivasoconstrictor effect of isradipine was of a specific type.	Isradipine	234-244	angiotensinogen	Rattus norvegicus	57-71
2523658-7	1989	Glomerular filtration rate and renal plasma flow showed a trend towards a dose-dependent rise; plasma renin activity was statistically increased (p less than 0.05) following the highest isradipine dose, whereas plasma aldosterone was unmodified.	Isradipine	186-196	renin	Homo sapiens	102-107
32107977-4	2021	It was found that calcium channel blockers (nimodipine, nilvadipine, nitrendipine, isradipine, and nifedipine) exhibit potential inhibitor properties for hCA I and hCA II.	Isradipine	83-93	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	154-170
2550243-4	1989	Isradipine increased the heart rate and this cardio-acceleration was potentiated by A II.	Isradipine	0-10	angiotensinogen	Homo sapiens	84-88
2453742-4	1988	The Kd values were similar to those previously reported, but the Bmax value on aorta SMC was higher than usually reported with other DHPs, showing that isradipine was a high full antagonist of calcium channel.	Isradipine	152-162	deoxyhypusine synthase	Bos taurus	133-137
2946507-9	1986	Renin level activity was increased slightly by isradipine.	Isradipine	47-57	renin	Homo sapiens	0-5
2459555-0	1988	The renin-angiotensin system modulates the peripheral vascular effects of the calcium antagonist isradipine in anesthetized rabbits.	Isradipine	97-107	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	4-9
2459555-8	1988	The isradipine-induced decrease of hepatic arterial and pancreatic blood flow was prevented and a similar tendency was observed in the spleen, stomach, small intestine, cecum, and arteriovenous shunt flow, indicating that the renin-angiotensin system was totally (liver, pancreas) or partially responsible for the effects of isradipine on these vessels.	Isradipine	4-14	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	226-231
2459555-8	1988	The isradipine-induced decrease of hepatic arterial and pancreatic blood flow was prevented and a similar tendency was observed in the spleen, stomach, small intestine, cecum, and arteriovenous shunt flow, indicating that the renin-angiotensin system was totally (liver, pancreas) or partially responsible for the effects of isradipine on these vessels.	Isradipine	325-335	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	226-231
2954832-0	1987	Similar increase in circulating renin after equihypotensive doses of nitroprusside, dihydralazine or isradipine in conscious rabbits.	Isradipine	101-111	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	32-37
31202801-11	2019	Isradipine, L-type Ca2+ channel specific blocker, further increased H2S-induced phosphorylation of PKC and ERK, showing an additive effect with H2S.	Isradipine	0-10	mitogen-activated protein kinase 1	Homo sapiens	107-110
31921405-9	2020	Mutation S652L increased the sensitivity of Cav1.3 for inhibition by the dihydropyridine L-type Ca2+-channel blocker isradipine by 3-4-fold.Conclusions and limitationsOur data provide evidence that gain-of-function CACNA1D mutations, such as S652L, but not loss-of-function mutations, such as S652W, cause high risk for neurodevelopmental disorders including autism.	Isradipine	117-127	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	44-50
31921405-9	2020	Mutation S652L increased the sensitivity of Cav1.3 for inhibition by the dihydropyridine L-type Ca2+-channel blocker isradipine by 3-4-fold.Conclusions and limitationsOur data provide evidence that gain-of-function CACNA1D mutations, such as S652L, but not loss-of-function mutations, such as S652W, cause high risk for neurodevelopmental disorders including autism.	Isradipine	117-127	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	215-222
31501511-5	2020	Utilizing fiber photometry to measure circuit activity in vivo in conjunction with the LTCC blocker, isradipine, we find that LTCCs drive differential recruitment of the PrL  NAcC pathway during cocaine- and stress-primed reinstatement.	Isradipine	101-111	prolactin	Mus musculus	170-173
30792921-1	2018	The objective was to develop a stable and non-compliance coated solid-lipid nanoparticles (coated SLN) using polymer (Eudragit L100) and lipoid (glycerol monostearate: soya lecithin) for partial dose reduction of isradipine [ISR; 2.5 mg by combination of bioenhancing agent (rutin; Ru) in equivalent ratio].	Isradipine	213-223	sarcolipin	Homo sapiens	98-101
28521299-5	2017	Our results showed that isradipine treatment prevented against MPTP-induced Cav1.2 and Cav1.3 calcium channel alpha1 subunits up-regulation in the SN.	Isradipine	24-34	calcium channel, voltage-dependent, L type, alpha 1C subunit	Mus musculus	76-82
29180017-8	2018	The increase in GSIS by OPN in diabetic human islets was Ca2+ dependent, which was abolished by Ca2+-channel inhibitor isradipine.	Isradipine	119-129	secreted phosphoprotein 1	Homo sapiens	24-27
29843108-5	2018	In this study, we identified a common binding mode for prominent DHPs nifedipine and isradipine using docking and pharmacophore analysis that is also able to explain the structure-activity relationship of a small subseries of DHP derivatives with a condensed ring system.	Isradipine	85-95	deoxyhypusine synthase	Homo sapiens	65-69
29708514-1	2018	The ability of the Cav1 channel inhibitor isradipine to slow the loss of substantia nigra pars compacta (SNc) dopaminergic (DA) neurons and the progression of Parkinson"s disease (PD) is being tested in a phase 3 human clinical trial.	Isradipine	42-52	caveolin 1	Homo sapiens	19-23
29038242-7	2017	A slow afterhyperpolarization in pyramidal cells was reduced by a selective block of CaV1 channels by isradipine, a CaMKII blocker, and siRNA knockdown of densin, and spike frequency increased upon selective block of CaV1 channel conductance.	Isradipine	102-112	caveolin 1	Homo sapiens	85-89
28521299-5	2017	Our results showed that isradipine treatment prevented against MPTP-induced Cav1.2 and Cav1.3 calcium channel alpha1 subunits up-regulation in the SN.	Isradipine	24-34	calcium channel, voltage-dependent, L type, alpha 1D subunit	Mus musculus	87-93
28592699-11	2017	Ca2+ influx through voltage-gated L-type Ca2+ channels (LTCCs), in particular Cav1.3, appears to contribute to this vulnerability, and the LTCC inhibitor isradipine is currently being tested as a neuroprotective agent for PD in a phase III clinical trial.	Isradipine	154-164	calcium channel, voltage-dependent, L type, alpha 1D subunit	Mus musculus	78-84
26674873-8	2015	The increase of intracellular calcium requires Cav1.3a channels, as a Cav1 calcium channel antagonist, isradipine, blocked the increase in calcium transients elicited by the agonist SKF-38393.	Isradipine	103-113	caveolin 1	Danio rerio	47-51
28592699-7	2017	Isradipine inhibition was splice variant and isoform dependent, with a 5- to 11-fold lower sensitivity to Cav1.3 variants during SN DA-like pacemaking compared with Cav1.2 during aSM-like activity.	Isradipine	0-10	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	106-112
28592699-7	2017	Isradipine inhibition was splice variant and isoform dependent, with a 5- to 11-fold lower sensitivity to Cav1.3 variants during SN DA-like pacemaking compared with Cav1.2 during aSM-like activity.	Isradipine	0-10	calcium channel, voltage-dependent, L type, alpha 1C subunit	Mus musculus	165-171
28701928-7	2017	This effect is specific for the SNpc subfield and largely mediated by L-Type calcium channels, as indicated by sensitivity to the CaV 1 blocker isradipine.	Isradipine	144-154	caveolin 1	Rattus norvegicus	130-135
27732883-9	2016	Tested CCBs inhibited enzyme activities of CYP3A4 (benidipine (+)>(-); felodipine (-)>(+); isradipine (-)-(+)) and CYP2C9 (benidipine (-)>(+); felodipine (+)>(-); isradipine (-)>(+)).	Isradipine	97-107	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
27732883-9	2016	Tested CCBs inhibited enzyme activities of CYP3A4 (benidipine (+)>(-); felodipine (-)>(+); isradipine (-)-(+)) and CYP2C9 (benidipine (-)>(+); felodipine (+)>(-); isradipine (-)>(+)).	Isradipine	175-185	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
27514537-8	2016	Treatment with isradipine was able to partially rescue these negative effects of CNTF-ACM (p < 0.05).	Isradipine	15-25	ciliary neurotrophic factor	Rattus norvegicus	81-85
26674873-8	2015	The increase of intracellular calcium requires Cav1.3a channels, as a Cav1 calcium channel antagonist, isradipine, blocked the increase in calcium transients elicited by the agonist SKF-38393.	Isradipine	103-113	caveolin 1	Danio rerio	70-74
25741585-5	2015	In conclusion, the preventative effect with PTX and CTX, and the absence of an effect with nifedipine, as well as the blockade by isradipine on cytosolic ET-1-induced increase in nuclear calcium, suggest that this nuclear calcium influx in hVSMCs is due to activation of the steady-state R-type calcium channel.	Isradipine	130-140	endothelin 1	Homo sapiens	154-158
26156385-2	2015	In experimental PD models, treatment with isradipine, the dihydropyridine with the highest affinity to Cav1.3 channels, prevents subthreshold calcium influx via Cav1.3 channels into midbrain dopamine neurons and protects them from mOS.	Isradipine	42-52	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	103-109
26156385-2	2015	In experimental PD models, treatment with isradipine, the dihydropyridine with the highest affinity to Cav1.3 channels, prevents subthreshold calcium influx via Cav1.3 channels into midbrain dopamine neurons and protects them from mOS.	Isradipine	42-52	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	161-167
26156385-2	2015	In experimental PD models, treatment with isradipine, the dihydropyridine with the highest affinity to Cav1.3 channels, prevents subthreshold calcium influx via Cav1.3 channels into midbrain dopamine neurons and protects them from mOS.	Isradipine	42-52	Moloney sarcoma oncogene	Mus musculus	231-234
26156385-3	2015	In DMV neurons, isradipine is also effective in reducing mOS despite overwhelming evidence that subthreshold calcium influx is negligible compared with spike-triggered influx.	Isradipine	16-26	Moloney sarcoma oncogene	Mus musculus	57-60
26156385-9	2015	We propose that the efficacy of isradipine in preventing mOS in DMV neurons arises from its mixed effect on Cav1.3 channels and on HVA Cav1.2 channels.	Isradipine	32-42	Moloney sarcoma oncogene	Mus musculus	57-60
26156385-9	2015	We propose that the efficacy of isradipine in preventing mOS in DMV neurons arises from its mixed effect on Cav1.3 channels and on HVA Cav1.2 channels.	Isradipine	32-42	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	108-114
26156385-9	2015	We propose that the efficacy of isradipine in preventing mOS in DMV neurons arises from its mixed effect on Cav1.3 channels and on HVA Cav1.2 channels.	Isradipine	32-42	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	135-141
24641324-1	2015	Isradipine (ISR) is a potent calcium channel blocker with low oral bioavailability due to low aqueous solubility, extensive first-pass metabolism and P-glycoprotein (P-gp)-mediated efflux transport.	Isradipine	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	150-164
24641324-1	2015	Isradipine (ISR) is a potent calcium channel blocker with low oral bioavailability due to low aqueous solubility, extensive first-pass metabolism and P-glycoprotein (P-gp)-mediated efflux transport.	Isradipine	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	166-170
26571400-5	2015	The depolarizing effect of GLP-1 on electrical activity was mimicked by the PKC activator PMA, occurred without activation of PKA, and persisted in the presence of PKA inhibitors, the KATP channel blocker tolbutamide, and the L-type Ca(2+) channel blocker isradipine; however, depolarization was abolished by lowering extracellular Na(+).	Isradipine	256-266	glucagon like peptide 1 receptor	Homo sapiens	27-32
24905310-1	2014	BACKGROUND: In this study, we investigated the in vitro effects of calcium channel blockers (nifedipine, nitrendipine, isradipine, and amlodipine besylate) on the activity of paraoxonase-1 (PON1).	Isradipine	119-129	paraoxonase 1	Homo sapiens	175-188
21737448-7	2011	Osmotic stress-induced JNK2 activation was abolished by BAPTA and isradipine, and partially reduced by extracellular Ca(2+) depletion, thapsigargin, or Ca(V)1.3 knockdown.	Isradipine	66-76	mitogen-activated protein kinase 9	Homo sapiens	23-27
23688558-7	2013	Some 1,4-dihydropyrimidines are more selective than isradipine for CaV1.3 over CaV1.2, shown here by both calcium flux and patch-clamp electrophysiology experiments, where the ratio of antagonism is around 2-3.	Isradipine	52-62	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	67-73
23688558-7	2013	Some 1,4-dihydropyrimidines are more selective than isradipine for CaV1.3 over CaV1.2, shown here by both calcium flux and patch-clamp electrophysiology experiments, where the ratio of antagonism is around 2-3.	Isradipine	52-62	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	79-85
23508108-2	2013	The GR has three SUMOylation sites: lysine 297 (K297) and K313 in the N-terminal domain (NTD) and K721 within the ligand-binding domain.	Isradipine	48-52	nuclear receptor subfamily 3 group C member 1	Homo sapiens	4-6
23032184-10	2013	Calpain 2, caspase 12 and 3 were increased in the Abeta treated animals which was partially antagonized by isradipine and nimodipine.	Isradipine	107-117	calpain 2	Rattus norvegicus	0-9
23032184-10	2013	Calpain 2, caspase 12 and 3 were increased in the Abeta treated animals which was partially antagonized by isradipine and nimodipine.	Isradipine	107-117	caspase 12	Rattus norvegicus	11-21
21925266-7	2011	Isradipine is a Federal Drug Administration-approved dihydropyridine calcium channel blocker that binds selectively to Ca(v)1.2 in the hippocampus.	Isradipine	0-10	immunoglobulin lambda variable 2-8	Homo sapiens	119-127
21925266-8	2011	Our studies have shown that isradipine in vitro attenuates beta amyloid oligomer toxicity by suppressing calcium influx into cytoplasm and by suppressing Ca(v)1.2 expression.	Isradipine	28-38	immunoglobulin lambda variable 2-8	Homo sapiens	154-162
21925266-10	2011	Our results further suggest that isradipine became bioavailable, lowered tau burden, and improved autophagy function in the brain.	Isradipine	33-43	microtubule associated protein tau	Homo sapiens	73-76
21925266-12	2011	This review highlights the importance of Ca(v)1.2 channel overexpression, the accumulation of hyperphosphorylated tau and suppression of autophagy in Alzheimer"s disease and modulation of this pathway by isradipine.	Isradipine	204-214	immunoglobulin lambda variable 2-8	Homo sapiens	41-49
24036210-7	2013	l-type calcium antagonist isradipine but not nimodipine further inhibited intracellular calcium overload after MPP(+) insult in Homer1 down-regulated neurons.	Isradipine	26-36	homer scaffold protein 1	Homo sapiens	128-134
21737448-8	2011	Osmotic stress rapidly induced c-Src activation, which was significantly attenuated by BAPTA, isradipine, or extracellular Ca(2+) depletion.	Isradipine	94-104	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	31-36
21487241-3	2011	What distinguishes snail and mammalian L-type channels is a difference in dihydropyridine sensitivity: 100 nM isradipine exhibits a significant block of mammalian Ca(v) 1.2 currents without effect on snail LCa(v)1 currents.	Isradipine	110-120	immunoglobulin lambda variable 2-8	Homo sapiens	163-172
21515375-6	2011	To test this hypothesis, the DHP with the highest affinity for Cav1.3L-type channels-isradipine-was systemically administered and then the DA toxin 6-OHDA injected intrastriatally.	Isradipine	85-95	caveolin 1, caveolae protein	Mus musculus	63-67
19385055-0	2009	Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory  impairment: Complementary roles of L-type calcium channel and NMDA receptors.	Isradipine	0-10	carbonic anhydrase 1	Rattus norvegicus	49-52
19385055-5	2009	Blocking of L-type calcium channels with isradipine reduced hypoxia-induced activation of calcium dependent xanthine oxidases, monoamine oxidases, cytosolic phospholipase A(2) and cycloxygenases (COX-2) along with concomitant decrease in free radical generation and cytochrome c release.	Isradipine	41-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	196-201
19385055-6	2009	Increased expression of calpain and caspase 3 was also observed following exposure to hypobaric hypoxia along with augmented neurodegeneration and memory impairment which was adequately prevented by isradipine administration.	Isradipine	199-209	caspase 3	Rattus norvegicus	36-45
10766758-2	2000	The role of the inactivated channel conformation in the molecular mechanism of Ca(2+) channel block by the 1,4-dihydropyridine (DHP) (+)-isradipine was analyzed in L-type channel constructs (alpha(1Lc); Berjukow, S., Gapp, F., Aczel, S., Sinnegger, M. J., Mitterdorfer, J., Glossmann, H., and Hering, S. (1999) J. Biol.	Isradipine	133-147	dihydropyrimidinase S homeolog	Xenopus laevis	128-131
15257873-7	2004	Also, isradipine raised the level of bFGF in the culture medium.	Isradipine	6-16	fibroblast growth factor 2	Homo sapiens	37-41
14744918-10	2004	The dihydropyridine (DHP) antagonist isradipine blocked Ca(v)1.4alpha1 with approximately 20-fold lower sensitivity than Ca(v)1.2alpha1.	Isradipine	37-47	dihydropyrimidinase	Mus musculus	21-24
14744918-10	2004	The dihydropyridine (DHP) antagonist isradipine blocked Ca(v)1.4alpha1 with approximately 20-fold lower sensitivity than Ca(v)1.2alpha1.	Isradipine	37-47	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	56-70
12853422-9	2003	The dihydropyridine (DHP)-antagonist isradipine blocked Cav1.4alpha1 with approximately 15-fold lower sensitivity than Cav1.2alpha1 and in a voltage-dependent manner.	Isradipine	37-47	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	56-68
11791031-5	2002	In bFGF-stimulated SMCs, amlodipine and isradipine reduced both Ca2+ influx and ERK 1/2 activation without affecting Ca2+ mobilization.	Isradipine	40-50	fibroblast growth factor 2	Homo sapiens	3-7
11791031-5	2002	In bFGF-stimulated SMCs, amlodipine and isradipine reduced both Ca2+ influx and ERK 1/2 activation without affecting Ca2+ mobilization.	Isradipine	40-50	mitogen-activated protein kinase 3	Homo sapiens	80-87
11728652-13	2001	According to the results of our in vitro study, magnesium sulphate and isradipine may have a beneficial effect on vascular resistance of cotyledon vessels in PIH in vivo, too.	Isradipine	71-81	pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included)	Homo sapiens	158-161
11560876-1	2001	The expression of three cytochromes P450 (CYP3A4, CYP2C9, and CYP2B6) was investigated in primary human hepatocyte cultures following treatment with four calcium channel modulators (CCM) of the dihydropyridine family, three antagonists (nifedipine, nicardipine, and isradipine), and one agonist (BK8644).	Isradipine	266-276	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
18703021-8	2008	Various non-Pgp substrates demonstrated inhibition of digoxin secretion (verapamil, mifepristone, clotrimazole, mevastatin, diltiazem and isradipine) but did not induce Pgp-mediated digoxin secretion.	Isradipine	138-148	ATP binding cassette subfamily B member 1	Homo sapiens	12-15
18353900-5	2008	Moreover, hBCs exhibited L-type voltage-activated Ca2+ currents (I Ca), which were selectively blocked by isradipine and verapamil and enhanced by the selective L-type agonist BAY K 8644.	Isradipine	106-116	BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone	Homo sapiens	10-14
12890513-7	2003	Radioligand binding studies revealed that the density of (+)[3H]isradipine binding sites in brain homogenates was reduced by 20-25% in CaV1.3 alpha 1(-/-) mice, without any detectable change in CaV1.2 (alpha 1C) protein levels as detected using Western blot analysis.	Isradipine	64-74	calcium channel, voltage-dependent, L type, alpha 1D subunit	Mus musculus	135-149
11791031-2	2002	Here, we investigated the effects of amlodipine and isradipine on Ca2+ movements and p42/p44 mitogen-activated protein kinase (ERK 1/2) activities, which are two early signalling events triggered by growth factors such as thrombin and basic fibroblast growth factor (bFGF).	Isradipine	52-62	cyclin dependent kinase 20	Homo sapiens	85-88
11791031-2	2002	Here, we investigated the effects of amlodipine and isradipine on Ca2+ movements and p42/p44 mitogen-activated protein kinase (ERK 1/2) activities, which are two early signalling events triggered by growth factors such as thrombin and basic fibroblast growth factor (bFGF).	Isradipine	52-62	coagulation factor II, thrombin	Homo sapiens	222-230
11487504-0	2001	Voltage-dependent acceleration of Ca(v)1.2 channel current decay by (+)- and (-)-isradipine.	Isradipine	77-91	calcium channel, voltage-dependent, L type, alpha 1C subunit S homeolog	Xenopus laevis	34-42
11487504-3	2001	To elucidate the underlying molecular mechanism we investigated the effects of (+)- and (-)-isradipine on Ca(v)1.2 inactivation gating at different membrane potentials.	Isradipine	88-102	calcium channel, voltage-dependent, L type, alpha 1C subunit S homeolog	Xenopus laevis	106-114
11487504-13	2001	In the voltage range between -25 and 20 mV where the channels inactivate predominantly from the open state the (+)- and (-)-isradipine-induced acceleration of the I(Ba) decay in V1504A displayed similar voltage-dependence as intrinsic fast inactivation of Ca(v)1.2.	Isradipine	120-134	calcium channel, voltage-dependent, L type, alpha 1C subunit S homeolog	Xenopus laevis	256-264
11487504-14	2001	Our data suggest that the isradipine-induced acceleration of the Ca(v)1.2 current decay reflects enhanced fast voltage-dependent inactivation and not open channel block.	Isradipine	26-36	calcium channel, voltage-dependent, L type, alpha 1C subunit S homeolog	Xenopus laevis	65-73
11179973-6	2001	After blocking known components of Ca2+ channel inward current in INS-1 cells by 2 microM (+/-)-isradipine plus 0.5 microM omega-conotoxin-MVIIC, the remaining current is reduced by 100 nM SNX-482 from -12.4 +/- 1.2 pA/pF to -7.6 +/- 0.5 pA/pF (n = 9).	Isradipine	90-106	insulin 1	Rattus norvegicus	66-71
11223467-5	2001	The densities of VDCC subtypes, determined by binding experiments using radiolabeled PN200 -110, omega-conotoxin GVIA and omega-conotoxin MVIIC, were found to be significantly decreased in aged synaptic plasma membranes.	Isradipine	85-95	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	17-21
10769189-3	2000	Binding of (+)-isradipine (K(i) 7.4 nM) and the non-benzoxadiazole DHPs nifedipine (K(i) 86 nM), (+/-)-nitrendipine (K(i) 33 nM) and (+/-)-nimodipine (K(i) 67 nM) to alpha1A(DHP) occurred at low nanomolar K(i) values.	Isradipine	11-25	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	166-173
10769189-3	2000	Binding of (+)-isradipine (K(i) 7.4 nM) and the non-benzoxadiazole DHPs nifedipine (K(i) 86 nM), (+/-)-nitrendipine (K(i) 33 nM) and (+/-)-nimodipine (K(i) 67 nM) to alpha1A(DHP) occurred at low nanomolar K(i) values.	Isradipine	11-25	dihydropyrimidinase	Homo sapiens	67-70
10769189-4	2000	DHP binding was highly stereoselective [25-fold higher affinity for (+)-isradipine].	Isradipine	68-82	dihydropyrimidinase	Homo sapiens	0-3
10466475-1	1999	OBJECTIVE: To study the effects of isradipine or metoprolol on insulin sensitivity and lipid profiles as well as on blood pressure and umbilical vascular resistance in pre-eclamptic women in the third trimester of pregnancy.	Isradipine	35-45	insulin	Homo sapiens	63-70
10777026-5	2000	During isradipine administration, blood pressure decreased from 151 +/- 3/91 +/- 2 to 130 +/-3/81 +/- 2 mm Hg (P < .01) without change in renal blood flow (406 +/- 43 to 425 +/- 52 mL/min/1.73m2, P = NS) or renal vascular resistance index (25,674 +/-3312 to 20,520 +/- 2311 dynes x sec x cm(-5)/m2, P = NS).	Isradipine	7-17	CD59 molecule (CD59 blood group)	Homo sapiens	187-192
10546924-1	1999	BACKGROUND: The calcium channel blockers mibefradil and isradipine inhibit CYP3A4 in vitro.	Isradipine	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
9655176-3	1998	Moreover, ET-1 and insulin-evoked sustained increases in Ca2+ influx were not attenuated by the selective PKC inhibitor, bisindolylmaleimide (BIS), or the specific L-type Ca2+ channel blocker, nifedipine, but were completely reversed by the R-type Ca2+ channel blocker, (-) PN 200-110 (isradipine).	Isradipine	270-284	insulin	Oryctolagus cuniculus	19-26
10088199-10	1998	In conclusion, this study has demonstrated that cGMP-enhancing agents, such as the naturally occurring ANP, the calcium channel blocker isradipine, and the synthetic inhibitor of PDE 3, were the most effective relaxants of ET-1 evoked contractions in pLAD in vitro.	Isradipine	136-146	endothelin 1	Homo sapiens	223-227
10051821-4	1998	Isradipine proved a good corrector of renal function after lithotripsy as it decreased enzymuria, promoted normalization of the activity of alkaline phosphatase, gamma-glutamyl transferase, alpha-glucosidase and lactate dehydrogenase to the end of the first postoperative month.	Isradipine	0-10	sucrase-isomaltase	Homo sapiens	190-207
10853442-2	1999	OBJECTIVE: We studied the effect of endothelin (ET)-1 on spontaneous contractions and the effects of nimodipine and isradipine on ET-1-induced contractions in myometrial tissue from normal and diabetic pregnant women.	Isradipine	116-126	endothelin 1	Homo sapiens	130-134
10853442-15	1999	The contractile effect of ET-1 in normal and diabetic myometrium is mediated partly by dihydropyridine-sensitive calcium channels since it is significantly reduced by nimodipine and isradipine.	Isradipine	182-192	endothelin 1	Homo sapiens	26-30
9849837-1	1998	BACKGROUND: To examine the effect of endothelin-1 (ET-1) on spontaneous contractile activity and the effects of nimodipine and isradipine on ET-1-induced contractile responses in myometrial strips isolated from normal pregnant and preeclamptic women.	Isradipine	127-137	endothelin 1	Homo sapiens	141-145
9849837-4	1998	The effect of increasing concentration of ET-1 on spontaneous contractions and effects of increasing concentration of nimodipine and isradipine on ET-1-induced contractions were recorded.	Isradipine	133-143	endothelin 1	Homo sapiens	147-151
9819242-2	1998	The slow IAHP was suppressed by the selective L-type Ca2+ channel antagonists isradipine (2 microM) or nifedipine (10 microM).	Isradipine	78-88	carbonic anhydrase 2	Rattus norvegicus	53-56
9655176-3	1998	Moreover, ET-1 and insulin-evoked sustained increases in Ca2+ influx were not attenuated by the selective PKC inhibitor, bisindolylmaleimide (BIS), or the specific L-type Ca2+ channel blocker, nifedipine, but were completely reversed by the R-type Ca2+ channel blocker, (-) PN 200-110 (isradipine).	Isradipine	286-296	insulin	Oryctolagus cuniculus	19-26
9655176-4	1998	These data suggest that both insulin and ET-1 activate the nifedipine-insensitive but isradipine-sensitive steady state voltage dependent R-type Ca2+ channels present on rabbit VSMCs and these channels are directly coupled to PTX and CTX sensitive G protein(s).	Isradipine	86-96	insulin	Oryctolagus cuniculus	29-36
9617753-0	1998	Effects of nimodipine and isradipine on endothelin-1-induced contraction of pregnant rat myometrium.	Isradipine	26-36	endothelin 1	Rattus norvegicus	40-52
9607315-4	1998	We investigated the sensitivity of Ca2+ channel splice variants derived from the human alpha1C gene to the DHP isradipine.	Isradipine	111-121	dihydropyrimidinase	Homo sapiens	107-110
9617753-1	1998	The purpose of this study was to investigate the effect of nimodipine and isradipine on endothelin-1-induced contractions of isolated pregnant rat myometrium.	Isradipine	74-84	endothelin 1	Rattus norvegicus	88-100
9617753-4	1998	After pretreatment for 30 min with 10(-6) M nimodipine or 10(-5) M isradipine, amplitude and duration of endothelin-1-induced contractions were significantly decreased, but frequency of myometrial contractions increased markedly.	Isradipine	67-77	endothelin 1	Rattus norvegicus	105-117
9514900-2	1998	The fluorescence enhancement was due to the binding of felodipine to high-affinity (Kd"s of 0.35 and 1.25 nM in cardiac SLM and skeletal SR, respectively) 1,4-dihydropyridine sites of the dihydropyridine receptor (DHPR), as evidenced in competition experiments with the DHP analog isradipine.	Isradipine	281-291	calcium voltage-gated channel subunit alpha1 S	Homo sapiens	188-212
9468004-6	1997	However a decrease in plasma beta-thromboglobulin levels was observed which reached statistical significance (P < 0.05) after 12 weeks treatment in the isradipine but not the atenolol group.	Isradipine	155-165	pro-platelet basic protein	Homo sapiens	29-49
9300583-0	1997	Interactions between darodipine or isradipine and the 5-HT1A receptor agonist 8-OHDPAT in rat brain.	Isradipine	35-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	54-60
9373050-11	1997	In conclusion, the antihypertensive effect of isradipine was more pronounced in low-renin EH patients, despite similar effects on renal function and UAE in both PRA groups.	Isradipine	46-56	renin	Homo sapiens	84-89
9300583-7	1997	A high dose of isradipine (1.60 mg/kg) or darodipine (5.0 mg/kg) left unchanged, or also enhanced, the signs of inhibition of serotonergic neurotransmission displayed by 8-OHDPAT, reducing but not suppressing the increase in the behavioral response to the stimulation of postsynaptic 5-HT1A receptors.	Isradipine	15-25	5-hydroxytryptamine receptor 1A	Rattus norvegicus	284-290
9300583-8	1997	It was speculated that the effects of isradipine and darodipine on scrotonergic pathways of rat brain could be due to changes in the back-regulation of the neurotransmission, mediated by 5-HT1A autoreceptors.	Isradipine	38-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	187-193
8913365-6	1996	Addition of Mg2+ revealed the presence of (+)-PN200-110 (DHP) binding sites with a Kd of 1 nM.	Isradipine	42-55	dihydropyrimidinase	Homo sapiens	57-60
9232324-5	1997	Nifedipine, isradipine, diltiazem, and verapamil dose-dependently inhibited the basic fibroblast growth factor (bFGF)-induced [3H]thymidine incorporation.	Isradipine	12-22	fibroblast growth factor 2	Homo sapiens	80-110
9232324-5	1997	Nifedipine, isradipine, diltiazem, and verapamil dose-dependently inhibited the basic fibroblast growth factor (bFGF)-induced [3H]thymidine incorporation.	Isradipine	12-22	fibroblast growth factor 2	Homo sapiens	112-116
9232324-6	1997	Fifty micromolars of nifedipine, isradipine, diltiazem, and verapamil completely inhibited bFGF-induced proliferation of HUAEC.	Isradipine	33-43	fibroblast growth factor 2	Homo sapiens	91-95
9232324-8	1997	Five micromolars of isradipine completely blocked the bFGF-induced BrdU incorporation.	Isradipine	20-30	fibroblast growth factor 2	Homo sapiens	54-58
8769587-10	1996	At 6 months, mean DBP decreased by 13.0 mm Hg in both groups, and mean SBP decreased by 19.5 mm Hg in hydrochlorothiazide and 16.0 mm Hg in isradipine (P=.002); the difference in SBP between the 2 groups persisted throughout the study but did not explain the increased incidence of vascular events in patients treated with isradipine.	Isradipine	140-150	selenium binding protein 1	Homo sapiens	71-74
8840947-9	1996	In this case-controlled retrospective series of renal transplant patients with documented CsA-TMA, the triple-drug combination of isradipine, aspirin, and pentoxifylline allowed for the successful reinstitution of CsA or conversion to FK506 in the setting of TMA, and resulted in increased transplant survival compared with previous reports.	Isradipine	130-140	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	90-93
8840947-9	1996	In this case-controlled retrospective series of renal transplant patients with documented CsA-TMA, the triple-drug combination of isradipine, aspirin, and pentoxifylline allowed for the successful reinstitution of CsA or conversion to FK506 in the setting of TMA, and resulted in increased transplant survival compared with previous reports.	Isradipine	130-140	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	214-217
8576944-3	1995	Here we demonstrate that the four Ca(2+)-channel blockers, Amlodipine, Felodipine, Isradipine and Manidipine, at nanomolar concentrations, activate the transcription of the genes encoding IL-6 and IL-8 in primary human VSMC and fibroblasts.	Isradipine	83-93	interleukin 6	Homo sapiens	188-192
8742912-6	1996	The results after Isradipine (n = 14) showed, at rest, a significant increase in LVEF and Pfr (51 +/- 9 to 54 +/- 8 and 1.97 +/- 0.44 to 2.36 +/- 0.71, respectively) and a decrease in DBP (93 +/- 11 to 87 +/- 13); and during exercise, a significant increase in LVEF (51 +/- 11 tot 55 +/- 13) and a decrease in ST segment depression (2.3 +/- 1.9 tot 1.9 +/- 1.6).	Isradipine	18-28	D-box binding PAR bZIP transcription factor	Homo sapiens	184-187
8880894-0	1996	Prostaglandin I2-mediated upregulation of 125I-LDL-receptor binding by isradipine in normo- and hypercholesterolemic rabbits in vivo.	Isradipine	71-81	low-density lipoprotein receptor	Oryctolagus cuniculus	47-59
8660111-0	1996	Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud"s phenomenon.	Isradipine	10-20	endothelin 1	Homo sapiens	24-36
7498985-4	1995	These results indicated that ACE was present but inhibited in the urine of isradipine-treated patients.	Isradipine	75-85	angiotensin I converting enzyme	Homo sapiens	29-32
7498985-5	1995	In vitro assays with ACE isolated from human urine and guinea pig plasma demonstrated that the enzyme is inhibited by isradipine and other commercially available calcium channel blockers, such as felodipine, nifedipine, and verapamil.	Isradipine	118-128	angiotensin I converting enzyme	Homo sapiens	21-24
8576944-3	1995	Here we demonstrate that the four Ca(2+)-channel blockers, Amlodipine, Felodipine, Isradipine and Manidipine, at nanomolar concentrations, activate the transcription of the genes encoding IL-6 and IL-8 in primary human VSMC and fibroblasts.	Isradipine	83-93	C-X-C motif chemokine ligand 8	Homo sapiens	197-201
7848351-5	1994	Fifteen hypertensive patients with microvascular angina (61 +/- 7 years, normal coronary angiogram, mild LV-hypertrophy) were treated with isradipine (CAS 75695-93-1) (5.3 +/- 0.9 mg/d) for 12 +/- 2 months.	Isradipine	139-149	BCAR1 scaffold protein, Cas family member	Homo sapiens	151-154
7496564-4	1995	Insufficient treatment response (DBP > 90 mmHg) led to addition of isradipine, and hydralazine was used as a tertiary drug if necessary.	Isradipine	70-80	D-box binding PAR bZIP transcription factor	Homo sapiens	33-36
7562626-7	1995	At 0.5 to 1 microM, DHP antagonists (nifedipine or (+)PN200-110) strongly inhibited RISC and also slowed the decay of intracellular Ca2+ concentration ([Ca2+]i) following repolarization after depolarization-induced Ca2+ release (-20 or -10 mV for 5 s).	Isradipine	51-63	serine carboxypeptidase 1	Rattus norvegicus	84-88
7729566-5	1995	The observed synergistic effect of bFGF and low levels of depolarization required influx of calcium since addition of the L-type calcium channel antagonists PN200-110 completely prevented neuronal survival.	Isradipine	157-166	fibroblast growth factor 2	Gallus gallus	35-39
7539048-6	1995	Moreover, the DHP antagonist, (+)-PN 200-110 (10 microM), greatly increased the percentage of null sweeps seen with the 14-pS channel.	Isradipine	30-44	dihydropyrimidinase	Homo sapiens	14-17
7794694-3	1995	HPLC experiments revealed that both isradipine enantiomers were bound to one class of high-affinity binding sites on the AAG molecule (n(S) = 0.83 +/- 0.05, Ka(S) = (1.33 +/- 0.25) x 10(6) l/mol, n(R) = 0.85 +/- 0.07, Ka(R) = (1.17 +/- 0.44) x 10(7) l/mol).	Isradipine	36-46	N-methylpurine DNA glycosylase	Homo sapiens	121-124
7723358-13	1995	Reducing BP with isradipine or atenolol results in a similar decrease in platelet activity and PAI-level, tested at rest and 1 h after rest, respectively.	Isradipine	17-27	serpin family E member 1	Homo sapiens	95-98
8587396-6	1995	Our results suggest that the sustained [Ca2+]i increase induced by ET-1, as with insulin, was mainly due to activation of a nifedipine-insensitive but isradipine-sensitive steady-state, voltage-dependent R-type calcium channel via an as yet unidentified ET receptor.	Isradipine	151-161	endothelin-1	Oryctolagus cuniculus	67-71
8587396-6	1995	Our results suggest that the sustained [Ca2+]i increase induced by ET-1, as with insulin, was mainly due to activation of a nifedipine-insensitive but isradipine-sensitive steady-state, voltage-dependent R-type calcium channel via an as yet unidentified ET receptor.	Isradipine	151-161	insulin	Oryctolagus cuniculus	81-88
7994851-14	1994	Isradipine significantly reduced the arterial wall collagen contents in both strains, with marked increases in the elastin content in the carotid but not in the aortic wall.	Isradipine	0-10	elastin	Rattus norvegicus	115-122
8045278-1	1994	Radioligand binding assays were performed with the selective antagonist of dihydropyridine-sensitive Ca2+ channels [3H]PN200-110 (isradipine) in rat vas deferens, before and 7 days after denervation, and data were compared with those obtained for K(+)-induced contractions, which are Ca(2+)-dependent.	Isradipine	119-128	carbonic anhydrase 2	Rattus norvegicus	101-104
7952882-11	1994	The dual L- and R-calcium channel blocker, isradipine (PN 200-110), but not the L-type calcium channel blocker, nifedipine, markedly reduced the PAF-induced vasoactive properties on both sides of the mesenteric vasculature.	Isradipine	43-53	PCNA clamp associated factor	Rattus norvegicus	145-148
7952882-11	1994	The dual L- and R-calcium channel blocker, isradipine (PN 200-110), but not the L-type calcium channel blocker, nifedipine, markedly reduced the PAF-induced vasoactive properties on both sides of the mesenteric vasculature.	Isradipine	55-65	PCNA clamp associated factor	Rattus norvegicus	145-148
7946179-10	1994	Addition of aspirin to nitrendipine produced a significant decrease and flattening of the beta-TG curve, whereas the combination of aspirin and isradipine was accompanied by a partial increase in plasma beta-TG levels.	Isradipine	144-154	pro-platelet basic protein	Homo sapiens	203-210
7946180-2	1994	The aim of this study was to investigate the in vitro influence of isradipine on ET-1-induced contraction of myometrial resistance arteries from pregnant women, as these vessels are partly responsible for the regulation of uteroplacental blood flow in preeclampsia.	Isradipine	67-77	endothelin 1	Homo sapiens	81-85
7946180-7	1994	Pretreatment with isradipine attenuated ET-1-induced contraction by 26% at 3 x 10(-4) mol/L and by up to 80% at 10(-3) mol/L.	Isradipine	18-28	endothelin 1	Homo sapiens	40-44
7946180-9	1994	The present study has thus shown that isradipine at high concentrations counteracts ET-1-induced constriction of myometrial arteries in term pregnant women.	Isradipine	38-48	endothelin 1	Homo sapiens	84-88
7946180-10	1994	Pretreatment with isradipine at high concentrations attenuates the ET-1 contraction.	Isradipine	18-28	endothelin 1	Homo sapiens	67-71
8045278-1	1994	Radioligand binding assays were performed with the selective antagonist of dihydropyridine-sensitive Ca2+ channels [3H]PN200-110 (isradipine) in rat vas deferens, before and 7 days after denervation, and data were compared with those obtained for K(+)-induced contractions, which are Ca(2+)-dependent.	Isradipine	130-140	carbonic anhydrase 2	Rattus norvegicus	101-104
8086326-2	1994	We attempted to verify the effectiveness of a new calcium antagonist, isradipine 5 mg SRO, on the reversal of left ventricular hypertrophy.	Isradipine	70-80	stomatin like 3	Homo sapiens	86-89
8205303-9	1994	Aspirin added to nitrendipine led to a further significant decrease in beta-TG levels whereas its addition to isradipine was accompanied by a partial increase in plasma beta-TG.	Isradipine	110-120	pro-platelet basic protein	Homo sapiens	169-176
8304366-8	1994	Antihypertensive efficacy was similar for the monotherapy drug regimens, with 84%, 71%, and 80% of patients receiving atenolol, enalapril, and isradipine, respectively, achieving DBP goal.	Isradipine	143-153	D-box binding PAR bZIP transcription factor	Homo sapiens	179-182
8205304-4	1994	The total binding affinity of isradipine to isolated LDL was markedly higher compared with amlodipine; total binding affinity (nKa) of isradipine vs amlodipine was (1.60 +/- 0.08) x 10(7) l/mol vs (4.14 +/- 0.33) x 10(6) l/mol, respectively.	Isradipine	30-40	tachykinin precursor 1	Homo sapiens	127-130
8205304-4	1994	The total binding affinity of isradipine to isolated LDL was markedly higher compared with amlodipine; total binding affinity (nKa) of isradipine vs amlodipine was (1.60 +/- 0.08) x 10(7) l/mol vs (4.14 +/- 0.33) x 10(6) l/mol, respectively.	Isradipine	135-145	tachykinin precursor 1	Homo sapiens	127-130
8205304-5	1994	Binding to HDL was also higher with isradipine --nKa = (1.04 +/- 0.04) x 10(5) l/mol--compared with that of amlodipine: nKa = (3.82 +/- 0.18) x 10(4) l/mol.	Isradipine	36-46	tachykinin precursor 1	Homo sapiens	49-52
8156652-5	1994	The results showed that BQ123 and the calcium antagonists nisoldipine, isradipine, nitrendipine and nifedipine fully relaxed IMA precontracted with 3 nmol/L ET-1 with the EC50 values of 7.18 +/- 0.09 (-log mol/L) for BQ123, and 7.68 +/- 0.07, 7.02 +/- 0.12, 6.96 +/- 0.08 and 6.89 +/- 0.09 for the calcium antagonists, respectively.	Isradipine	71-81	endothelin 1	Homo sapiens	157-161
8301097-10	1993	In the case of c-fos, pre-incubation with 5 x 10(-6) mol/l isradipine led to a decrease in both Ang II- and PDGF-induced expression of this immediate-early gene.	Isradipine	59-69	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-20
8301097-10	1993	In the case of c-fos, pre-incubation with 5 x 10(-6) mol/l isradipine led to a decrease in both Ang II- and PDGF-induced expression of this immediate-early gene.	Isradipine	59-69	angiotensinogen	Homo sapiens	96-102
8396506-2	1993	In the present study, we have determined the effects of isradipine, a dihydropyridine calcium antagonist, on Ang II- or ET-induced constriction of afferent arterioles (AAs) and efferent arterioles (EAs) using the isolated perfused hydronephrotic kidney.	Isradipine	56-66	angiotensinogen	Homo sapiens	109-115
8258429-2	1993	The newly developed sustained-release form of isradipine (Vascal uno/Lomir SRO) releases the active substance continuously from a gel matrix over a period of 24 hours.	Isradipine	46-56	stomatin like 3	Homo sapiens	75-78
8396506-5	1993	However, Ang II-induced AA constriction was more sensitive to isradipine than ET-induced constriction (half-maximal inhibitory concentration [IC50], 1.2 +/- 0.2 nmol/L [n = 12] versus 170 +/- 65 nmol/L [n = 19]; P < .01).	Isradipine	62-72	angiotensinogen	Homo sapiens	9-15
8396506-6	1993	The sensitivity of Ang II-induced AA constriction to isradipine was identical to that of KCI-induced AA constriction (IC50, 4.2 +/- 0.9 nmol/L; n = 12).	Isradipine	53-63	angiotensinogen	Homo sapiens	19-25
8205314-10	1993	However, the isradipine group had a significantly lower DBP than the felodipine group at the conclusion of the study (p = 0.008; 95% CI 0.7 to 6.9 mmHg).	Isradipine	13-23	D-box binding PAR bZIP transcription factor	Homo sapiens	56-59
8242226-1	1993	By the use of fura-2 and digital imaging techniques, [K]o depolarization or PAF (10(-9) M) were shown to induce a sustained increase of [Ca]i in human or canine single aortic vascular endothelial cells (VEC) that was insensitive to nifedipine but sensitive to (-)-PN200-110 or to lowering of [Ca]o.	Isradipine	260-273	carbonic anhydrase 1	Homo sapiens	137-141
8240458-1	1993	In this multicenter, placebo-controlled study, 16 patients with mild to moderate essential hypertension were treated with 10 mg/day isradipine retard (PN 200-110, Lomir SRO, CAS 75695-93-1) for 3 weeks.	Isradipine	132-142	BCAR1 scaffold protein, Cas family member	Homo sapiens	174-177
7692173-4	1993	As compared with placebo, isradipine RF decreased daytime BP by 10 mm Hg systolic (SBP, p < 0.001) and by 6 mm Hg diastolic (DBP, p < 0.01), and night SBP and DBP by 7 (p < 0.05) and 3 mm Hg (P = NS), respectively.	Isradipine	26-36	selenium binding protein 1	Homo sapiens	83-86
7692173-4	1993	As compared with placebo, isradipine RF decreased daytime BP by 10 mm Hg systolic (SBP, p < 0.001) and by 6 mm Hg diastolic (DBP, p < 0.01), and night SBP and DBP by 7 (p < 0.05) and 3 mm Hg (P = NS), respectively.	Isradipine	26-36	selenium binding protein 1	Homo sapiens	157-160
7692173-5	1993	Isradipine MR reduced the daytime SBP 8 mm Hg (p < 0.05) and DBP by 3 mm Hg (p = NS), and the night SBP by 1 mm Hg (p = NS) and DBP by < 1 mm Hg (P = NS).	Isradipine	0-10	selenium binding protein 1	Homo sapiens	34-37
7692173-5	1993	Isradipine MR reduced the daytime SBP 8 mm Hg (p < 0.05) and DBP by 3 mm Hg (p = NS), and the night SBP by 1 mm Hg (p = NS) and DBP by < 1 mm Hg (P = NS).	Isradipine	0-10	selenium binding protein 1	Homo sapiens	103-106
8388325-12	1993	The thrombin-induced contraction of portal vein strips was completely inhibited by isradipine, and thrombin did not produce an increase in cytosolic [Ca2+], measured by indo-1 fluorescence in cells clamped at -50 mV, sufficient to activate Ca(2+)-dependent chloride current.	Isradipine	83-93	coagulation factor II	Rattus norvegicus	4-12
8484785-4	1993	Experiments in the presence of the dihydropyridine calcium blocker isradipine suggest that the lipoprotein-induced Egr-1 mRNA induction occurs via a Ca2+ dependent pathway.	Isradipine	67-77	early growth response 1	Rattus norvegicus	115-120
8466717-2	1993	Significant linear correlations were found between the antihypertensive effect of isradipine and plasma levels of total cholesterol and high-density lipoprotein (HDL2 or HDL3) in normotriglyceridemic (n = 63), but not in hypertriglyceridemic (n = 22), patients.	Isradipine	82-92	junctophilin 3	Homo sapiens	162-166
8466717-2	1993	Significant linear correlations were found between the antihypertensive effect of isradipine and plasma levels of total cholesterol and high-density lipoprotein (HDL2 or HDL3) in normotriglyceridemic (n = 63), but not in hypertriglyceridemic (n = 22), patients.	Isradipine	82-92	HDL3	Homo sapiens	170-174
8466742-6	1993	Plasma levels of beta-thromboglobulin (beta-TG) and platelet aggregation (PA) were measured six times over 24 h. Isradipine and nitrendipine significantly lowered systolic and diastolic blood pressure.	Isradipine	113-123	pro-platelet basic protein	Homo sapiens	17-37
8466742-6	1993	Plasma levels of beta-thromboglobulin (beta-TG) and platelet aggregation (PA) were measured six times over 24 h. Isradipine and nitrendipine significantly lowered systolic and diastolic blood pressure.	Isradipine	113-123	pro-platelet basic protein	Homo sapiens	39-46
8466742-9	1993	Aspirin added to nitrendipine produced a significant decrease in beta-TG levels whereas isradipine plus aspirin was accompanied by a partial increase in beta-TG.	Isradipine	88-98	pro-platelet basic protein	Homo sapiens	153-160
8193733-3	1993	Arterial pressure was significantly reduced by isradipine, with mean reduction in systolic blood pressure of 11.0 mmHg and diastolic pressure of 13.2 mmHg over 24 h. There was no significant change in heart rate, endogenous creatinine clearance, serum biochemistry or plasma renin activity.	Isradipine	47-57	renin	Homo sapiens	275-280
8426093-3	1993	Our results show that nifedipine and PN200-110 inhibit the PHA-dependent production of interleukin-2 except when 12-O-tetradecanoyl-13-O-acetyl phorbol is added to the cultures.	Isradipine	37-46	interleukin 2	Homo sapiens	87-100